Skip to main content

Advertisement

Table 3 Relevance and novelty of conclusion claims based on manual validation

From: Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness

Drug ClinicalTrials.gov Published results from ClinicalTrials.gov
  studies involving the drug studies involving the drug
   N Relevant N (%) Novel (indication) Novel (off-label use)
Antidepressants      
Citalopram 4 25 5 (20) 5  
Duloxetine 4 4 4 (100) 3  
Escitalopram 6 9 3 (33) 1 2
Mirtazapine 1 22 1 (5) 1 0
Nortriptyline 3 24 2 (8) 1 1
Venlafaxine 2 2 2 (100) 1 1
Antipsychotics      
Olanzapine 5 13 7 (54) 6 1
Risperidone 23 70 26 (37) 21 5
Sedative Hypnotics      
Eszopiclone 1 1 1 (100) 0 1
  1. The relevance and novelty of conclusion claims linked from three Linked Data drug information sources to the product labeling for nine randomly selected psychotropic drugs.